These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


373 related items for PubMed ID: 20955961

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Hepatobiliary disease in patients with cystic fibrosis.
    Moyer K, Balistreri W.
    Curr Opin Gastroenterol; 2009 May; 25(3):272-8. PubMed ID: 19381084
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.
    Desmond CP, Wilson J, Bailey M, Clark D, Roberts SK.
    Liver Int; 2007 Dec; 27(10):1402-8. PubMed ID: 18036103
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Liver disease in cystic fibrosis.
    Colombo C, Russo MC, Zazzeron L, Romano G.
    J Pediatr Gastroenterol Nutr; 2006 Jul; 43 Suppl 1():S49-55. PubMed ID: 16819402
    [Abstract] [Full Text] [Related]

  • 8. A single centre experience of liver disease in adults with cystic fibrosis 1995-2006.
    Nash KL, Allison ME, McKeon D, Lomas DJ, Haworth CS, Bilton D, Alexander GJ.
    J Cyst Fibros; 2008 May; 7(3):252-7. PubMed ID: 18042441
    [Abstract] [Full Text] [Related]

  • 9. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
    O'Brien SM, Campbell GR, Burke AF, Maguire OC, Rowlands BJ, FitzGerald MX, Hegarty JE.
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Hepatobiliary abnormalities and disease in cystic fibrosis: epidemiology and outcomes through adulthood.
    Bhardwaj S, Canlas K, Kahi C, Temkit M, Molleston J, Ober M, Howenstine M, Kwo PY.
    J Clin Gastroenterol; 2009 Oct; 43(9):858-64. PubMed ID: 19525864
    [Abstract] [Full Text] [Related]

  • 12. Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease.
    Siano M, De Gregorio F, Boggia B, Sepe A, Ferri P, Buonpensiero P, Di Pasqua A, Raia V.
    Dig Liver Dis; 2010 Jun; 42(6):428-31. PubMed ID: 20034860
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Hepatobiliary complications of cystic fibrosis.
    Feranchak AP.
    Curr Gastroenterol Rep; 2004 Jun; 6(3):231-9. PubMed ID: 15128491
    [Abstract] [Full Text] [Related]

  • 15. Expression of delta F508 cystic fibrosis transmembrane conductance regulator protein and related chloride transport properties in the gallbladder epithelium from cystic fibrosis patients.
    Dray-Charier N, Paul A, Scoazec JY, Veissière D, Mergey M, Capeau J, Soubrane O, Housset C.
    Hepatology; 1999 Jun; 29(6):1624-34. PubMed ID: 10347100
    [Abstract] [Full Text] [Related]

  • 16. Management of liver disease and portal hypertension in cystic fibrosis: a review.
    Colombo C, Lanfranchi C, Tosetti G, Corti F, Primignani M.
    Expert Rev Respir Med; 2024 May; 18(5):269-281. PubMed ID: 38962827
    [Abstract] [Full Text] [Related]

  • 17. Hepatic Manifestations of Cystic Fibrosis.
    Sakiani S, Kleiner DE, Heller T, Koh C.
    Clin Liver Dis; 2019 May; 23(2):263-277. PubMed ID: 30947876
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Lack of association of common cystic fibrosis transmembrane conductance regulator gene mutations with primary sclerosing cholangitis.
    Gallegos-Orozco JF, E Yurk C, Wang N, Rakela J, Charlton MR, Cutting GR, Balan V.
    Am J Gastroenterol; 2005 Apr; 100(4):874-8. PubMed ID: 15784035
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 19.